|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to residues 351-365 of human DRAK2.|
|Contains||0.02% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Western Blot (WB)||2-4 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Suggested positive control: antigen standard for STK17B (transient overexpression lysate), Raji whole cell lysate.
Protein kinases play important roles in the signal transduction in response to a variety of external stimuli. Recently, several protein kinases have been identified that may also be involved in apoptotic process. Overexpression of a serine/threonine kinase, ZIP kinase can cause the morphological changes typical of apoptosis in NIH 3T3 cells (1). Sanjo et al, have identified two new protein kinases DRAK1 and DRAK2 (Death Receptor Associated Kinase 1 and 2) (1). Both DRAKs and ZIP kinase share significant homology at the amino acid level (1,2). The kinase domains of both DRAKs, ZIP kinase are homologous to DAP (Death-associated protein) kinase, which is involved in the apoptotic signaling induced by interferon-g. Overexpression of DRAKs in NIH 3T3 cells lead to apoptosis. These transfection experiments suggest that C-terminal domain of DRAKs are important for induction of apoptosis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.